Search | Clinical Trials Finder

Conditions: Non-squamous, Non-Small Cell Lung Cancer
Interventions: Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab, Docetaxel; Biological · Drug
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab; Drug · Other · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: carboxyamidotriazole, placebo, quality-of-life assessment, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Ipilimumab, Radiotherapy (IMRT or 3-D CRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 87
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more

Conditions: Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
Interventions: Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab; Radiation · Drug
Lead sponsor: Mark Bernard; Other
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Megan Daly, MD; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium, Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, Magnetic Resonance Imaging, Photoimmunotherapy, Positron Emission Tomography, Robotic Bronchoscopy, Video-Assisted Thoracic Surgery; Procedure · Biological · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Imprime PGG® Injection, Bevacizumab, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Fayetteville, Arkansas • Canton, Ohio • San Antonio, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: pemetrexed, gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • Shreveport, Louisiana + 1 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions: amifostine trihydrate, cisplatin, docetaxel; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 13
States / cities: Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions: Arm A, Arm B; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: Sotorasib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pegilodecakin, Nivolumab; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Tempe, Arizona • Beverly Hills, California • Los Angeles, California + 30 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Docetaxel, Oxaliplatin, Bevacizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Lung Cancer
Interventions: Temozolomide; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Waukesha, Wisconsin

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery; Other · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Houston, Texas

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 79
States / cities: Tucson, Arizona • Corona, California • Duarte, California + 63 more

Conditions: Non-Small-Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 29
States / cities: San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more

Conditions: Non-small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Interventions: KB-GDT-01; Biological
Lead sponsor: Kiromic BioPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tucson, Arizona • Beverly Hills, California • Pittsburgh, Pennsylvania + 2 more

Conditions: Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
Interventions: imexon, docetaxel; Drug
Lead sponsor: AmpliMed Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: TLK286, cisplatin; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas

Search by objective public record fields.

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)